Pre-Exposure Prophylaxis for HIV Prevention in Women: Current Perspectives

by Charlene A Flash, Sannisha K Dale, Douglas S Krakower
International Journal of Women’s Health (May 2017), 9: 391–401

11 pp. 308 kB
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5459979/pdf/ijwh-9-391.pdf

Previous studies have demonstrated that oral HIV pre-exposure prophylaxis (PrEP), the use of antiretroviral medications by HIV-uninfected persons to prevent HIV acquisition, can reduce HIV incidence among women who are adherent to PrEP. However, to date, awareness and uptake of PrEP among women have been very limited, suggesting a need for innovative strategies to increase the knowledge of and access to PrEP among women in diverse settings. This narrative review summarizes the efficacy and safety data of PrEP in women, discusses considerations related to medication adherence for women who use PrEP, and highlights behavioral, social, and structural barriers to maximize the effectiveness of PrEP in women. It also reviews novel modalities for PrEP in women which are being developed and tested.

(Visited 8 times, 1 visits today)
This entry was posted in Essential Medicines, General, HIV - AIDS - STI, Maternal & Child Health. Bookmark the permalink.